

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
1440.1027-005

APPLICATION NO.  
09/543,371

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

December 12, 2001

(Use several sheets if necessary)

APPLICANT  
Raghuram Kalluri

FILING DATE  
April 4, 2000

GROUP  
1644

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AL3	WO 99/65940	23 DEC 1999	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AW6	Colorado, P.C. et al., 1999, "Arresten: Angiogenesis and Renal Cell Carcinoma Tumor Inhibiting Matrix Protein", J. Amer. Soc. Nephrol. 10:489A
AX6	Colorado, P.C. et al., 2000, "Anti-Angiogenic Cues From Vascular Basement Membrane Collagen", Cancer Res. 60:2520-2526
AY6	Kamphaus, G.D. et al., 1999, "Canstatin: A Novel Matrix Derived Inhibitor of Angiogenesis and Renal Cell Carcinoma Tumor Growth", J. Amer. Soc. Nephrol. 10:495A
AZ6	Kefalides, N.A. et al., 1999, "Suppression of Tumor Cell Growth By Type IV Collagen and a Peptide From the NC1 Domain of the $\alpha 3$ (IV) Chain", Medicina 59:553
AR7	Maeshima, Y. et al., 2000, "Two RGD-Independent $\alpha_v\beta_3$ Integrin Binding Sites on Tumstatin Regulate Distinct Anti-Tumor Properties", J. Biol. Chem. 275:23745-23750
AS7	Nickols, A. et al., 1997, "Antiangiogenic and anticancer Activities of Antagonists of Integrin $\alpha_v\beta_3$ ", Proc. Ann. Mtg. Amer. Assoc. Cancer Res. 38:206
AT7	Varner, J.A., 1997, "The Role of Vascular Cell Integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ in Angiogenesis", Regulation of Angiogenesis, Biurkhauser Verlag, Basel, Switzerland, pp. 361-390

EXAMINER

DATE CONSIDERED

3/5/02

RECEIVED

JAN 17 2002

TECH CENTER 1600/2900

*[Signature]*